Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
FBRX vs CVM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
FBRX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–3 Matrix Metrics)
FBRX Overall Winner
6-Pillar Tally: FBRX 3 – 2 CVM (1 Tie)
Matrix Metrics: FBRX 5 – 3 CVM
As of Nov 16, 2026, Forte Biosciences, Inc. (FBRX) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). FBRX carries a Unified Composite Score of 52.7/100 (HOLD) at $76.99 (N/M Forward P/E, 0.0% operating margin), whereas CVM carries 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. FBRX 52.7/100 HOLD), FBRX captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -62.7% YoY).
- Technical & Structure Timing Caution: FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About FBRX vs CVM
FBRX
Head-to-Head Winner
Forte Biosciences, Inc. Common Stock
$76.99
+0.03% 1D
Market Cap
$1.6B
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.09β · 3% Vol
Unified Composite Score
52.7
HOLD
Tech 49.0
Fund 51.0
Flow 62.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
CVM
Cel-Sci Corporation
$1.59
+24.22% 1D
Market Cap
$20.9M
TTM Revenue
$28,558
Forward P/E
23.0x
Beta / 30D Vol
0.65β · 120% Vol
Unified Composite Score
56.6
HOLD
Tech 60.0
Fund 54.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (FBRX 3 – 2 CVM)
1. Valuation Multiples
CVM
Forward P/E
N/M
23.0x
Trailing P/E
N/M
23.0x
PEG Ratio
N/M
1.12x
EV / Revenue
N/M
N/M
2. Growth & Scale
FBRX
Revenue Growth (YoY)
+0.0%
-62.7%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$28,558
Market Cap
$1.6B
$20.9M
3. Profitability & Quality
FBRX
Gross Margin
N/A
N/A
Operating Margin
0.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-62.3%
-252.5%
4. Balance Sheet & Cash Flow
CVM
Cash Generation (TTM)
-$72M
-$17M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$7.52 Book/Sh · -62.3% ROE
$6.6M Net Debt (1.24x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
FBRX
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
11.1% (3rd %ile)
N/A (N/A)
Put/Call OI Skew
0.77x (Call-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: FBRX (5) vs CVM (3)| Institutional Metric | FBRX | CVM | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.6B | $20.9M | FBRX | |
| Trailing P/E Ratio | N/M | 23.0x | CVM | |
| Forward P/E Ratio | N/M | 23.0x | CVM | |
| Revenue Growth (YoY) | +0.0% | -62.7% | FBRX | |
| Operating Margin (TTM) | 0.0% | 0.0% | Tie | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -62.3% | -252.5% | FBRX | |
| 52-Week Range Position | 100% ($10–$77) | 10% ($1–$8) | FBRX | |
| Beta / 30D Volatility | 1.09β · 3% Vol | 0.65β · 120% Vol | FBRX | |
| Unified Institutional Score | 52.7 / 100 (HOLD) | 56.6 / 100 (HOLD) | CVM | |
| Trailing 12M Revenue (USD) | N/A | $28,558 | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | 1.12x PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$72M ($7.52 Book/Sh · -62.3% ROE) | -$17M ($6.6M Net Debt (1.24x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CVM +33.73 pp
3M Horizon
FBRX +244.41 pp
6M Horizon
FBRX +234.04 pp
1Y Horizon
FBRX +682.88 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | FBRX Revenue | CVM Revenue | FBRX Op. Margin | CVM Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2011 | N/A | $0M | N/A | -1881.0% | CVM |
| FY2012 | N/A | $0M | N/A | -6772.3% | CVM |
| FY2013 | N/A | $0M | N/A | -12450.1% | CVM |
| FY2014 | N/A | $0M | N/A | -9721.4% | CVM |
| FY2016 | $0M | N/A | -64673.5% | N/A | FBRX |
| FY2017 | $0M | N/A | -91775.6% | N/A | FBRX |
| FY2018 | $20M | N/A | -254.2% | N/A | FBRX |
| FY2019 | $0M | N/A | -11288.9% | N/A | FBRX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
FBRX
UNCLASSIFIED
Current IV
11.1%
IV Percentile
3rd %ile
Put/Call OI Skew
0.77x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact FBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CVM
BREAKDOWN
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
FBRX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CVM Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ FBRX vs CVM Key Questions & Quantitative Answers
As of Nov 16, 2026, Forte Biosciences, Inc. (FBRX) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). FBRX carries a Unified Composite Score of 52.7/100 (HOLD) at $76.99 (N/M Forward P/E, 0.0% operating margin), whereas CVM carries 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. FBRX 52.7/100 HOLD), FBRX captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -62.7% YoY). Technical & Structure Timing Caution: FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FBRX leads the Growth & Scale pillar: FBRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CVM at -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2011 to FY2019), FBRX cumulative revenue shifted N/A while CVM shifted N/A. In operating R&D and SG&A reinvestment, FBRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CVM.
CVM screens cheaper on headline valuation multiples. FBRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FBRX (-62.3% ROE) versus CVM (-252.5% ROE) capital efficiency.
In options market volatility and institutional positioning, FBRX carries 11.1% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.09β · 3% Vol realized risk). By comparison, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CVM vs FBRX · Reverse Pair
FBRX vs KRSA
· Sector Peer
FBRX vs DMRA
· Sector Peer
CVM vs AGEN
· Sector Peer
CVM vs BCRX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma